# Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

> **NCT05539157** · PHASE1 · UNKNOWN · sponsor: **Immorna Biotherapeutics, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Cutaneous Tumor
- Malignant Solid Tumor

## Interventions

- **DRUG:** JCXH-211

## Key facts

- **NCT ID:** NCT05539157
- **Lead sponsor:** Immorna Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-18
- **Primary completion:** 2024-03
- **Final completion:** 2024-05
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05539157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05539157, "Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05539157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*